News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,066 Results
Type
Article (39150)
Company Profile (283)
Press Release (648633)
Section
Business (203902)
Career Advice (1996)
Deals (35372)
Drug Delivery (89)
Drug Development (80852)
Employer Resources (168)
FDA (16099)
Job Trends (14808)
News (344645)
Policy (32450)
Tag
Academia (2530)
Alliances (49187)
Alzheimer's disease (1262)
Approvals (16063)
Artificial intelligence (146)
Bankruptcy (352)
Best Places to Work (11582)
Biotechnology (200)
Breast cancer (190)
Cancer (1377)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (282)
Clinical research (64714)
Collaboration (486)
Compensation (264)
COVID-19 (2542)
C-suite (109)
Data (1395)
Diabetes (177)
Diagnostics (6170)
Earnings (84895)
Employer resources (146)
Events (110021)
Executive appointments (397)
FDA (16788)
Funding (434)
Gene therapy (196)
GLP-1 (599)
Government (4333)
Healthcare (18697)
Infectious disease (2635)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16347)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7864)
Lung cancer (198)
Manufacturing (207)
Medical device (13214)
Medtech (13219)
Mergers & acquisitions (19198)
Metabolic disorders (461)
Neuroscience (1585)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1705)
Obesity (262)
Opinion (183)
Parkinson's disease (98)
Patents (121)
People (56464)
Phase I (20131)
Phase II (28500)
Phase III (21242)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (264)
Real estate (5891)
Regulatory (21685)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1472)
Startups (3562)
United States (15263)
Vaccines (564)
Weight loss (182)
Date
Last 7 days (174)
Last 30 days (2035)
Last 365 days (35175)
2024 (35174)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (196)
Asia (37284)
Australia (6087)
California (3839)
Canada (1461)
China (311)
Colorado (173)
Connecticut (178)
Europe (79841)
Florida (538)
Georgia (136)
Illinois (387)
Indiana (225)
Maryland (637)
Massachusetts (2979)
Michigan (175)
Minnesota (292)
New Jersey (1109)
New York (1094)
North Carolina (743)
Northern California (1705)
Ohio (146)
Pennsylvania (930)
South America (1092)
Southern California (1472)
Texas (555)
Utah (108)
Washington State (401)
688,066 Results for "orphomed inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients
OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced positive results from the recent Phase 2 study of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D).
January 4, 2022
·
6 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Press Releases
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
December 20, 2024
·
2 min read
Press Releases
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
·
19 min read
Press Releases
BRIJ Medical, Inc. Awarded Breakthrough Technology Agreement in the Non-Invasive Skin Closure Category with Premier, Inc.
December 17, 2024
·
2 min read
Press Releases
CorMedix Inc. Added to Nasdaq Biotechnology Index
December 20, 2024
·
1 min read
Press Releases
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
November 26, 2024
·
9 min read
Press Releases
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
December 24, 2024
·
5 min read
Press Releases
Scott Burger Appointed as CEO of AngioInsight, Inc.
December 17, 2024
·
2 min read
Drug Development
OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that its ORP-101 molecule successfully passed a second interim futility analysis triggered by enrollment of 260 patients in its Phase 2 clinical trial for treatment of irritable bowel syndrome with diarrhea (IBS-D).
April 14, 2021
·
4 min read
1 of 68,807
Next
